How will 'Indian Ozempics' change treatment for diabetes and obesity?

On March 20 this year, the patent for semaglutide, which is the active ingredient of blockbuster drug Ozempic, expired in India. The country was ready: nearly 40 generics are either in the market now or will be out soon. The story of Ozempic and weight-loss drugs falling under the GLP-1 category, is now a few years old, though studies continue to research how these drug impact the human body. Up until now, its costs had put it out of the reach of most Indians. That has changed now, with the costs of the generics much lower than that of the original. In a country where nearly a quarter of the population is either overweight or obese and where 1 in 10 adults live with diabetes, how is this going to impact obesity and diabetes treatment? And should these drugs be all we rely on? Listen in. Guest: Dr. V. Mohan, chairman, Dr. Mohan’s Diabetes Specialities Centre and Madras Diabetes Research Foundation, Chennai Host: Zubeda Hamid Producer: Jude Francis Weston Learn more about your ad choices. Visit megaphone.fm/adchoices